---
figid: PMC9671114__fcimb-12-965471-g006
figtitle: Changes and significance of gut microbiota in children with focal epilepsy
  before and after treatment
organisms:
- Mus musculus
- Rattus norvegicus
- Escherichia coli O104H4
- Diaporthe sclerotioides
- Subgroup C
- Escherichia coli
- gut metagenome
- Trigonella foenum-graecum
- Homo sapiens
organisms_ner:
- Mus musculus
- Homo sapiens
- Rattus norvegicus
- Drosophila melanogaster
pmcid: PMC9671114
filename: fcimb-12-965471-g006.jpg
figlink: /pmc/articles/PMC9671114/figure/f6/
number: F6
caption: 'level 3 Metabolic pathway analysis based on a pairwise comparison among
  the three groups. (A) Comparison between the pre-treatment subgroup and the control
  group. (B) Comparison between the pre-treatment subgroup and the post-treatment
  subgroup. (C) Comparison between the post-treatment subgroup and the control subgroup.
  (D, E) Differences in alanine, aspartate, glutamate metabolism, and differences
  in citrate cycle (TCA cycle), respectively. *FDR<0.05, **FDR<0.01, ***FDR<0.001.
  Red: upregulation. D: pre-treatment group, S: post-treatment group, J: control group.'
papertitle: Changes and significance of gut microbiota in children with focal epilepsy
  before and after treatment.
reftext: Changci Zhou, et al. Front Cell Infect Microbiol. 2022;12:965471.
year: '2022'
doi: 10.3389/fcimb.2022.965471
journal_title: Frontiers in Cellular and Infection Microbiology
journal_nlm_ta: Front Cell Infect Microbiol
publisher_name: Frontiers Media S.A.
keywords: gut microbiota | epilepsy | focal onset | children | 16S rDNA gene sequencing
automl_pathway: 0.6108845
figid_alias: PMC9671114__F6
figtype: Figure
redirect_from: /figures/PMC9671114__F6
ndex: ''
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC9671114__fcimb-12-965471-g006.html
  '@type': Dataset
  description: 'level 3 Metabolic pathway analysis based on a pairwise comparison
    among the three groups. (A) Comparison between the pre-treatment subgroup and
    the control group. (B) Comparison between the pre-treatment subgroup and the post-treatment
    subgroup. (C) Comparison between the post-treatment subgroup and the control subgroup.
    (D, E) Differences in alanine, aspartate, glutamate metabolism, and differences
    in citrate cycle (TCA cycle), respectively. *FDR<0.05, **FDR<0.01, ***FDR<0.001.
    Red: upregulation. D: pre-treatment group, S: post-treatment group, J: control
    group.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - Naga
  - Bad
  - Gnat2
  - Das
  - da
  - Bglap3
  - Gpi1
  - Hgd
  - Synpr
  - Mal
  - Tirap
  - Mrtfa
  - Tnip3
  - Grhl2
  - am
  - Soat1
  - Rabep2
  - NAGA
  - BAD
  - TBX1
  - RPRD1B
  - SI
  - SMIM1
  - GNAO1
  - GNAI1
  - GNAI2
  - GNAI3
  - GNAT1
  - GNAT2
  - GNAT3
  - GNAZ
  - HGD
  - CDK9
  - XS
  - LPO
  - SYNPR
  - MAL
  - MRTFA
  - TIRAP
  - PNMA1
  - EXT1
  - EXTL1
  - EXTL2
  - EXTL3
  - EXT2
  - TNIP3
  - GRHL2
  - TMEM258
  - GJB2
  - ACAD8
  - ACAD9
  - ACADL
  - ACADM
  - ACADS
  - ACADVL
  - ACAD10
  - ACAD11
  - ACADSB
  - GCDH
  - IVD
  - FOLR1
  - FOSL1
  - RABEP2
  - Ccne1
  - Lipa
  - Si
  - Pnma1
  - CkIIbeta
  - Andorra
  - Anp
  - Acam
  - Sh
  - vis
  - achi
  - cass
  - we
  - de
  - hh
  - nAChRalpha6
  - Ube3a
  - nAChRalpha2
  - op
  - ca
  - E(spl)malpha-BFM
  - Det
  - Dys
  - oc
  - fy
  - CycE
  - cyc
  - ali
  - alpha-Est7
  - Vel
  - tak
  - Tak1
  - Takl2
  - spo
  - mal
  - bs
  - Mrtf
  - Ext
  - ss
  - La
  - BomBc3
  - kud
  - gom
  - hid
  - so
  - dome
  - du
  - Mcad
  - fra
  - kay
  - bol
  - TCA
  - TCA CYCLE
  - Fatty acid
  - Val
  - KOO
  - Si
  - Acetyl
  - Theoban
  - o scalidokas
  - HID
---
